ArticleApplied biochemistry and biotechnology2023
Antagonist Impact of Selenium-Based Nanoparticles Against Mycobacterium tuberculosis.
Article in Applied biochemistry and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Promising Roles of Selenium Nanoparticles in Anti-Tuberculosis Therapy: Opportunities and Challenges.International journal of nanomedicine · 2026Review
- Nanomaterial-mediated host directed therapy of tuberculosis by manipulating macrophage autophagy.Journal of nanobiotechnology · 2024Review
- Polyethylene Glycol-Based Polymer-Drug Conjugates: Novel Design and Synthesis Strategies for Enhanced Therapeutic Efficacy and Targeted Drug Delivery.Applied biochemistry and biotechnology · 2024Review
- Nano-delivery Systems and Therapeutic Applications of Phytodrug Mangiferin.Applied biochemistry and biotechnology · 2024Review
- Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
- Retraction · 2024-08-14Concerns/Issues about Referencing/Attributions · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Plagiarism of Image · Plagiarism of Text · · See also: https://pubpeer.com/publications/F9A89E3388C3E5DA4D03ABA4D11919
- Retracted
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the cardinal causes of global deaths from a single-point infectious agent has been reported to be tuberculosis (or TB). At present times, the incidence of TB cases occurs mostly due to multi-drug resistance, which is expected to boost further in the upcoming times. Accordingly, the development of alternative treatment methodologies has received significant research interest. In this regard, the application of nanoparticles has notable cognizance. The literature suggested that nanoparticles have substantial potential to be used as the delivery medium for drug injection as well as they also serve as a potential bactericidal agent. In this present study, the efficacy of the selenium nanoparticles against the inhibition of growth of Mycobacterium tuberculosis was evaluated. The obtained results indicated that the synthesized selenium nanoparticles have notable cognizance towards the inhibition of growth of Mycobacterium tuberculosis by disrupting the integrity of their cell envelope. This study thus proposes a novel approach and opens new dimensional avenues in the field of nanoparticle-induced cell disruption strategies.
Indexed as
Identifiers
36637700What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.